This page shows the latest Amjevita news and features for those working in and with pharma, biotech and healthcare.
The Humira market is worth more than $15bn annually and, in addition to Boehringer's Cyltezo (adalimumab-adbm), other biosimilars that are set to launch in 2023 include Amgen’s Amjevita
Amgen’s agreement was slightly different in that US sales of its Amjevita biosimilar can start from January 31, and both deals include royalty payments to AbbVie, although the details of
Pharma giant hopes its candidate will follow in the footsteps of Amgen’s Amjevita and BI’s Cyltezo. ... The biosimilar is vying to be the third copycat version of AbbVie’s Humira (adalimumab) in the big US market after Amgen’s Amjevita and
Amgen secured approval in Europe for its biosimilar under the Amgevita brand name in March and in the US as Amjevita a year ago, said that the drug will be one
the go-ahead for its product - known as Amjevita in the US market - in September 2016.
It is the second to claim marketing approval in the US market after Amgen's Amjevita (adalimumab-atto), which got the go-ahead in September 2016. ... AbbVie is claiming patent protection for Humira in the US out to 2022 and has already taken legal action
More from news
Approximately 2 fully matching, plus 8 partially matching documents found.
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...